Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Spondylitis, Ankylosing
Interventions: tocilizumab, Placebo; Biological · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more

Conditions: Small Bowel Crohn's Disease
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psoriatic Arthritis
Interventions: Methotrexate, Anti-TNF; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Axial Spondyloarthritis
Interventions: Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, DMARDs; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Crohn Disease
Interventions: certolizumab pegol (CDP870, CZP), Placebo; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more

Conditions: Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions: REN-1654; Drug
Lead sponsor: Renovis; Industry
Eligibility: 55 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 16
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more

Conditions: Diabetes Mellitus, Type I
Interventions: Purified Pancreatic Islets, Etanercept; Biological · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pediatric Crohn's Disease
Interventions: Methotrexate, Sugar pill (placebo); Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 20 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more

Conditions: Rheumatoid Arthritis
Interventions: Anti-TNF-alpha, Methotrexate, Placebo, RO7123520; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, TNF Inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions: TILT-123, Avelumab; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: MEDI2070, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 26
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 22 more

Conditions: Rheumatoid Arthritis
Interventions: Teriparatide, calcium citrate, Vitamin D, TNF antagonist; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts

Conditions: Pancreatitis, Chronic; Diabetes; Transplant
Interventions: etanercept, Alpha 1-Antitrypsin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab, Placebo, methotrexate (MTX); Drug · Other
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Daytona Beach, Florida • Miami, Florida • Palm Harbor, Florida + 6 more

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Conditions: Pemphigus Vulgaris
Interventions: Enbrel (Etanercept); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Interventions: Anti-CD19 CAR-T cells; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions: TILT-123, pembrolizumab, pegylated liposomal doxorubicin; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Cerebral Palsy
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 1,067 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more

Search by objective public record fields.

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

Response Assessment in SB CD

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Rheumatoid Arthritis Memory B Cells and Abatacept

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

Infliximab for the Treatment of Early Rheumatoid Arthritis

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Long Term Open Label Continuation Study

An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Inflammatory Cytokines Associated With Perinatal Brain Injury